Shingles Vaccine and Dementia Risk 2026: What the UK NHS Evidence Actually Shows

A UK explainer for May 2026. A 2025 Nature paper used a strict-age-cut-off shingles vaccine rollout in Wales to show a 20 percent lower dementia risk over 7 years in vaccinated adults. The NHS now uses Shingrix for adults aged 65 and 70 to 79, and severely immunosuppressed adults 18 and over.

A December 2025 paper in Cell expanded on this by extending the study to people already diagnosed with dementia. In the UK, the current recommended shingles vaccine is Shingrix, which is offered routinely to anyone turning 65, adults aged 70 to 79 inclusive and severely immunosuppressed adults at age 18 or older. Although the dementia-protection signal comes from observation and not a randomised trial, it is consistent and significant.

Imagine you are in your late sixties. Your mum has died of Alzheimer’s disease. A news report on BBC One in Autumn 2025 reports that a routine vaccination that is being given to people over 70 has also slashed the risk of dementia by 20%. You call your GP, hoping to get it. This explainer runs you through the true meaning of the science.

What the Welsh natural experiment actually showed

On 1 September 2013, NHS Wales started to offer the Zostavax vaccine as a single-dose vaccine – which was then considered adequate for most. It did this with one single criterion: if you were going to be 79 years of age or older on or after that date. The age then dropped by one year every programme cycle and if you had already had your 80th birthday before that date, you could never have the vaccine under NHS Wales programmes ever again. The reasoning was supply limitation than scientific choice, yet it created almost identical groups of older Welsh people: one group of vaccinated 78-year-olds, versus a group of unvaccinated 80-year-olds.

Pascal Geldsetzer and Markus Eyting at Stanford University in California analyzed a decade’s worth of primary care data (which had been anonymised by a third party and supplied to researchers under data use agreements) for just over 280,000 individuals between ages 71 to 88 in Wales. They reported in the journal Nature in April 2025 that those who received the shingles vaccine had a 20% lower rate of new dementia diagnoses than those unvaccinated over 7 years of follow-up (Hazard ratio: 0.80). This result was statistically significant and remained robust to multiple tests performed by the researchers (including checking if the people who got vaccinated simply led healthier lives) and was strong in women than in men and exclusive to dementia cases, with no evidence of other benefits.

Their research created a ‘natural experiment’ design that closely mimics the random-assignment in a clinical trial, where vaccination was dictated purely by the calendar than choice. And in late 2025, a further study by the same group published in the peer-reviewed journal Nature Medicine extended the research to cover the newer Shingrix vaccine, finding an equally strong or even stronger protective signal in relation to dementia incidence and in terms of slower dementia disease progression in the case of already living with dementia.

Shingrix versus Zostavax – Why the UK now uses Shingrix

Two shingles vaccines are available worldwide: Zostavax, produced by Merck. It uses a live-attenuated (weakened) virus. It was licensed in the US in 2006 and in the UK in 2013. Zostavax provided only partial protection – around 50%. Critically, it was considered unsafe for people with weakened immune systems, because the weakened live virus could potentially reactivate.

Shingrix, manufactured by GSK, is a recombinant protein vaccine adjuvanted with a novel adjuvant called AS01B. It was licensed in the US in 2017 and in the UK in 2018. Shingrix is much more effective than Zostavax at preventing shingles, reducing diagnosed cases by over 90% and it is safe for people with impaired immune systems.

In 2021, the NHS decided to offer the Shingrix vaccine, exclusively. The rollout process involved retiring Zostavax completely by the end of 2024 and moving entirely to Shingrix. The Nature study published in April 2025 used Welsh data from when Zostavax was given. This means that the data that underpinned this remarkable finding were based on the use of Zostavax. As seen from the 2025 study in Nature Medicine, the effects with the new Shingrix vaccine are similarly strong or stronger – indicating that the dementia risk protection seen is not limited to the earlier vaccine.

Shingrix is provided as a two-dose vaccine: For people in standard vaccine groups (ages 65-79), the doses are given 6 to 12 months apart. For those who are severely immunosuppressed, the schedule is shortened to 8 weeks to 6 months apart. Each dose is a single jab into the upper arm and protection lasts at least 10 years, with no need for boosters.

Shingrix, the recombinant vaccine now used by the NHS, is more effective and safe for immunocompromised individuals.

The 2026 NHS shingles vaccine eligibility in plain terms

From 2026, there are three main eligibility groups for the Shingles Vaccine on the NHS.

1. Adults turning 65 or older on or after 1 September 2023: This followed an April 2023 JCVI recommendation to lower the vaccine age from 70 to 65. Anyone turning 65 (or more) between September 2023 and August 2024 will be offered the jab around their 65th birthday via their GP surgery.

2. Adults aged 70 to 79 inclusive: There are transitional arrangements for people aged 65 or over who had their 65th birthday between September 2023 and August 2024 (when they might have already been offered the jab at 65): in these cases, you are now eligible at 70, not 65, since this is a lower vaccination age. All adults aged between 70 and 79 (inclusive) will remain eligible for their first dose up until their 80th birthday. The second dose can be taken up until your 81st birthday.

3. Severely immunosuppressed adults aged 18 or over: This includes anyone with a weakened immune system: stem cell or solid organ transplant recipients, those on chemotherapy for cancer, those undergoing therapy with high-dose corticosteroids, biological therapies (including TNF inhibitors), individuals living with HIV and with a low CD4 cell count, people with primary immunodeficiency (congenital or inherited immunodeficiencies) and anyone undergoing immunosuppressive therapy following organ transplant. For these individuals, the schedule consists of two vaccine doses separated by 8 weeks to 6 months.

If you are 80 years or over and did not receive the shingles vaccine when eligible during your younger years, the NHS will no longer cover the cost of Shingrix. In such instances, you may opt for private vaccination. Shingrix is commercially available at high street pharmacies, including Boots, Superdrug, LloydsPharmacy, Pharmacy2U and Asda Online Doctor. The vaccine is expected to cost approximately £200-240 per dose, with the full two-dose course costing between £400-480.

Likely mechanism, what we do and do not know

There are three biological pathways through which shingles vaccinations might have some protective effect on dementia: They are not mutually exclusive.

1. Neuro-inflammation: Chickenpox, caused by the varicella zoster virus, lies dormant in your nervous system forever. When it is reactivated as shingles, nerve pain and damage in your nervous system can occur. Even without symptomatic signs of a shingles outbreak, a low level of lifelong chronic brain inflammation, that is implicated in dementia, can be driven by such asymptomatic reactivation of shingles virus in the body. A vaccination would prevent such reactivation, reducing a possible trigger.

2. Adjuvant effect: The newer Shingrix vaccine uses a powerful adjuvant called AS01B. This provides broad training of the immune system like the non-specific boosting that gives BCG (tuberculosis vaccine) effectiveness in multiple health conditions. This adjuvant may strengthen the immune system’s vigilance and efficiency at clearing away harmful protein buildup in the brain – like beta-amyloid.

3. Preventing post-herpetic neuralgia: It is possible Shingrix reduces dementia risk because it helps to prevent the well-known but often transient decline in cognitive performance that frequently results from shingles and post-herpetic neuralgia (PHN) where people suffer lifelong nerve pain following an outbreak of shingles.

What is clear is that the dementia-protection effect comes solely from the observations. It does not yet have proof from randomised controlled clinical trials (RCTs). As you read later, the “natural experiment” designed for studying shingles and dementia in Wales, in April 2025, was strong and close to simulating random assignment. With such strong observational data, a future trial specifically for dementia protection would now be ethically tricky. To date, the association has proven specific to shingles vaccinations. No similar benefits were observed in people receiving flu, pneumococcal or Covid vaccinations. More insights will be published soon based on ongoing studies into the new Shingrix vaccine, especially from other countries around the world analyzing the impact of their national vaccination programs.

Safety profile of Shingrix and what to expect

Shingrix has a well-documented safety profile. One notable common side effect is its reactogenicity – it commonly triggers an immune reaction that is obvious and noticeable in the short term.

The side effects typically appear within 24 hours after vaccination and usually disappear in 2 to 3 days. These side effects are a sign that the immune system is working to protect you from shingles. A low dose of paracetamol or ibuprofen taken after your vaccination for the aches and temperature is usually perfectly fine and safe, if recommended by your pharmacist or doctor. Sensible planning can involve arranging your vaccine so you do not need to drive for long hours the following morning. The second dose can be expected to create a similar – and in some people, an even milder – reaction as the first dose.

Rarely serious side effects, such as Guillain-Barre Syndrome (estimated to occur in roughly 1 in 70,000 to 100,000 doses) or bursitis (inflammation of the shoulder bursa), are serious and monitored closely by UK’s MHRA Yellow Card scheme for vaccine reporting. Severe allergic reaction (anaphylaxis) is rare. Epinephrine is available to treat any severe allergic reaction on-site at a GP surgery or pharmacy. Anyone who gets the vaccine is asked to remain on-site for a brief observation period post-injection. You must inform the clinician if you have ever experienced a severe allergic reaction to any ingredient of Shingrix.

Importantly, Shingrix can be given safely at the same time as other recommended adult vaccines, such as the seasonal flu jab, Covid-19 mRNA boosters and pneumococcal vaccine. It is generally advised to get them injected into opposite arms of the body to minimise discomfort. The MHRA continues to scrutinise new real-world safety data relating to Shingrix.

Practical steps for a UK adult in 2026

1. Check Your NHS Eligibility: The easiest guide is to determine if you are within the ages of 65 and 79 inclusive this year (2026). If so, you are eligible for the Shingles vaccine on the NHS. For those turning 65 between September 2023 and August 2025, the practice should contact you at around the time of your birthday. If not, you must phone the GP to book a shingles jab.

2. 80 and 81 Year Olds (Missed Second Dose): Contact your GP practice and check if it is still possible to book your second dose, as this can be administered up to your 81st birthday under NHS programmes.

3. Over 80 Years (Never Vaccinated): If you are over 80 and missed your designated eligible period, the shingles vaccine is not provided free under the NHS. However, you may decide to pay for the vaccine privately. The Shingrix vaccine is readily available at various retail pharmacies (Boots, Superdrug, LloydsPharmacy, Pharmacy2U, Asda Online Doctor), costing between roughly £200 and £240 per dose. This means the full two-dose course would run to £400-480.

4. Severely Immunosuppressed: Regardless of age, if you are severely immunocompromised (as per the criteria listed earlier), you are entitled to the shingles vaccine. Schedule a consultation with your specialist hospital doctor or GP to discuss eligibility.

5. Vaccine is Preventative: Do not wait until you have been diagnosed with shingles to consider getting vaccinated, do it in advance.

6. Part of Brain Health Strategy: The shingles vaccine is not a standalone measure for a healthy brain. Integrate it into a wider brain health regime: Use hearing aids if needed, diligently monitor blood pressure, actively maintain a social and physically active life and effectively manage conditions such as diabetes. In 2024, the Lancet Commission identified 14 manageable modifiable risk factors for preventing dementia.

Frequently Asked Questions

Does the shingles vaccine really reduce the risk of dementia by 20%?

Yes. A 2025 Nature study discovered that by using a natural experiment design (where vaccination allocation was by calendar month, mimicking random assignment) in Wales, adults who had the shingles vaccine were found to be 20% less likely to have developed dementia over a 7-year period. Although the finding is observational than coming from a large-scale clinical trial, it relies on a robust study design. In 2025, another Nature Medicine study reported similar effects with the newer Shingrix vaccine and a slowdown in dementia among people already diagnosed with the disease.

What type of shingles vaccine does the UK use nowadays?

The UK NHS exclusively uses Shingrix now. This is a recombinant, non-live, adjuvanted protein vaccine manufactured by GSK. Since 2021, it has replaced the older live vaccine, Zostavax. This replacement process was finished by 2024. Shingrix is more effective at preventing shingles and it is considered safe for use in people with weakened immune systems. Shingrix is provided as two injections, typically 6 to 12 months apart for regular vaccine recipients and 8 weeks to 6 months apart for immunocompromised adults.

Who is eligible for the shingles vaccine on the NHS in 2026?

The current criteria cover three main groups: 1. All adults turning 65 or older from September 1, 2023. 2. All adults aged between 70 and 79 inclusive. 3. All adults aged 18 and over with a compromised immune system. You are eligible for your first dose up until your 80th birthday and the second dose can be administered up to your 81st birthday.

What if I am over 80? How can I still get the shingles vaccine?

If you are over the age of 80 and did not have your shingles vaccine when you were younger and eligible, you will not be provided it for free on the NHS. However, you can choose to pay for the Shingles vaccine privately at high street pharmacies including Boots, Superdrug, LloydsPharmacy, Pharmacy2U and Asda Online Doctor. Expect to pay £200-240 per dose, bringing the full course cost to somewhere between £400 and £480.

What are the most frequent side effects associated with Shingrix?

The common side effects are pain, redness and swelling at the vaccination site, which most people experience. Half of people get fatigue, muscle pain or a headache. In about one out of ten cases, a mild fever will appear. These are all normal reactions that show your immune system responding properly. Most side effects clear up in two to three days. Paracetamol can safely ease symptoms if needed.

Is the dementia-protective effect of the shingles vaccine likely to be confirmed through a randomized controlled trial?

No. A traditional, placebo-controlled trial is not expected to occur. The current observational evidence suggesting a link is already strong, making it unethical to withhold a vaccine for a disease as common and severe as dementia from one group in a trial. Confirmation will instead come from subsequent observational studies, possibly in other populations around the globe, as well as further research into the precise mechanisms at play in the brain.

Should I get the shingles vaccine purely for the potential reduction in dementia risk?

The shingles vaccine is recommended primarily to prevent shingles, an intensely painful and disruptive illness. The observed potential to reduce dementia risk is considered a bonus benefit, on top of the existing proven benefits against shingles. If you fit into any of the eligible age groups (65-79), the vaccine is certainly worth having for its primary function of preventing shingles itself. The findings relating to dementia only serve as another reason to accept the vaccine when offered.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.